Gilead expects remdesivir to drive P&L rebound by year-end

Gilead bumped up its full year guidance Thursday after projecting to manufacture 2 million treatment courses of its COVID-19 antiviral remdesivir by year-end, and sell 1-1.5 million courses even as the company reported 2Q20 earnings below expectations.

Gilead Sciences Inc. (NASDAQ:GILD) now expects full-year EPS of $6.25-$7.65, up from its prior target of $6.05-$6.45. The company also guided for revenues of $23-$25 billion, an increase from its previous $21.8-$22.2 billion range...